News Releases | BioAtla, Inc

Date
5/11/22	First Patients Dosed in Phase 2 Platform Clinical Trial Testing Novel Immunotherapy Combinations in Highly Malignant Ovarian Cancer
5/4/22	BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress
4/8/22	BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022
3/1/22	BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
1/10/22	BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors